Search Results - "Othman, Tamer"

Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia by Othman, Tamer A, Azenkot, Tali, Moskoff, Benjamin N, Tenold, Matthew E, Jonas, Brian A

“…Elderly and/or unfit patients with acute myeloid leukemia have historically been challenging to manage as they were ineligible for what was considered standard…”
Get full text

Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents by Othman, Tamer A., Mei, Matthew, Zhang, Jianying, Aldoss, Ibrahim, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Pullarkat, Vinod

Get full text

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma by Othman, Tamer, Frankel, Paul, Allen, Pamela, Popplewell, Leslie L, Shouse, Geoffrey, Siddiqi, Tanya, Danilov, Alexey V, Ruel, Nora, Daniels, Shari, Peters, Lacolle, Khoo, Stella, Rosen, Steven T, Sharon, Elad, Villalona-Calero, Miguel, Ruel, Christopher, Tuscano, Joseph, Herrera, Alex F

“…Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation…”
Get full text

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy by Othman, Tamer A., Zhang, Jianying, Mei, Matthew, Stein, Anthony S., Forman, Stephen J., Marcucci, Guido, Pullarkat, Vinod, Aldoss, Ibrahim

Get full text

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia by Othman, Tamer A, Tenold, Matthew E, Moskoff, Benjamin N, Azenkot, Tali, Jonas, Brian A

“…Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have…”
Get more information

Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade by Uche, An, Huynh, Karen, Abdelkarim, Ayman, Othman, Tamer, Lee, Jennifer

“…Factor X deficiency is a rare bleeding disorder that varies in the severity of its clinical manifestations. The symptoms of this disorder can occur at any age,…”
Get full text

Combined Cerebellar and Spinal Cord Deficits Caused by an Underlying Gynecologic Malignancy by Park, Susan, Vankina, Ritika, Hendizadeh, Moshe-Samuel, Othman, Tamer, Kim, Phyllis

“…Paraneoplastic cerebellar degeneration (PCD) is an uncommon autoimmune disorder targeting antigens within the nervous system and is usually associated with an…”
Get full text

Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study by Badar, Talha, Narra, Ravi, Mims, Alice S., Heckman, Michael G., Shallis, Rory M., Fahad, Sheikh, Hunter, Cameron, Kota, Vamsi, Othman, Tamer Adel, Jonas, Brian, Desai, Shreya, Camargo Correia, Guilherme Sacchi, Patel, Anand, DuVall, Adam S., Palmisiano, Neil, Curran, Emily, Omer, Zulfa, Advani, Anjali, Atallah, Ehab, Litzow, Mark

“…Intensive chemotherapy (IC) combination with second‐ or third‐generation TKI improves survival compared to non‐IC with first‐generation TKI. Allo‐HCT was…”
Get full text

Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next‐Generation Sequencing in Detecting Actionable Driver Mutations in Anti‐EGFR Naive Metastatic Colorectal Cancer by Gupta, Rohan, Othman, Tamer, Chen, Chen, Sandhu, Jaideep, Ouyang, Ching, Fakih, Marwan

“…Background Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic…”
Get full text

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? by Othman, Tamer, Herrera, Alex, Mei, Matthew

“…Purpose of Review The standard of care for relapsed/refractory (r/r) Hodgkin lymphoma (HL) patients is autologous stem cell transplantation (ASCT) for patients…”
Get full text

Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma by Othman, Tamer, Lowsky, Robert, Richman, Carol, Hoeg, Rasmus, Abedi, Mehrdad, Tuscano, Joseph

Get full text

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma by Othman, Tamer, Rosenberg, Aaron S, Timmerman, John, Heyman, Benjamin, Abdulhaq, Haifaa, Tuscano, Joseph M

Get full text

The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL by Othman, Tamer, Logan, Aaron C, Muffly, Lori, Leonard, Jessica, Park, Jae, Shah, Bijal, Aldoss, Ibrahim

“…CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia…”
Get more information

Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant by Ladbury, Colton, Kambhampati Thiruvengadam, Swetha, Othman, Tamer, Hao, Claire, Chen, Lu, Wong, Jeffrey, Cao, Thai, Herrera, Alex, Mei, Matthew, Dandapani, Savita

“…Approximately 50% of patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) will relapse post–autologous stem cell transplant (ASCT), and…”
Get full text

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens by Krackeler, Margaret Li, Moskoff, Benjamin, Othman, Tamer, Azenkot, Tali, Beechinor, Ryan J., Rosenberg, Aaron S, Esteghamat, Naseem S, Hoeg, Rasmus T, Tuscano, Joseph M, Jonas, Brian A.

Get full text

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis by Othman, Tamer, Quan, Michelle A., Zhang, Shiliang, Gaut, Daria, Young, Patricia A., Abdulhaq, Haifaa, Shieh, Kevin, Reid, Jack, Brem, Elizabeth A., Heyman, Benjamin, Tuscano, Joseph

Get full text

Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia by Othman, Tamer, Koller, Paul, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Tinajero, Jose, Ali, Haris, Cai, Ji‐Lian, Mei, Matthew, Aribi, Ahmed, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Aldoss, Ibrahim

Get full text

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma by Othman, Tamer, Baird, John H., Pak, Stacy, Mei, Matthew, Herrera, Alex F., Mansour, Joshua, Shouse, Geoffrey, Sahebi, Firoozeh, Spielberger, Ricardo, Cai, Ji‐Lian, Farol, Leonardo, Godfrey, James, Kallam, Avyakta, Phillips, Tycel, Popplewell, Leslie, Siddiqi, Tanya, Forman, Stephen, Budde, Lihua E.

Get full text

Favorable Survival Outcomes in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Fludarabine/Melphalan-Conditioning with Tacrolimus/Sirolimus-Based Gvhd Prophylaxis by Salhotra, Amandeep, Al Malki, Monzr M., Yang, Dongyun, Mokhtari, Sally, Aldoss, Ibrahim, Aribi, Ahmed, Amanam, Idoroenyi, Ali, Haris, Sandhu, Karamjeet S., Agrawal, Vaibhav, Koller, Paul B., Ball, Brian J., Arslan, Shukaib, Otoukesh, Salman, Blackmon, Amanda, Pourhassan, Hoda, Samara, Yazeed, Othman, Tamer, Becker, Pamela S., Pullarkat, Vinod, Spielberger, Ricardo, Stewart, Forest Marc, Smith, Eileen Patricia, Artz, Andrew, Forman, Stephen J., Marcucci, Guido, Stein, Anthony, Nakamura, Ryotaro

“…Introduction: Fludarabine/melphalan (F/M) conditioning is associated with superior disease-free survival (DFS) compared to busulfan-based reduced-intensity…”
Get full text

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia by Othman, Tamer, Koller, Paul B., Tsai, NI-Chun, Ngo, Dat, Chen, Jason, Blackmon, Amanda, Pourhassan, Hoda, Agrawal, Vaibhav, Amanam, Idoroenyi, Ball, Brian J., Otoukesh, Salman, Salhotra, Amandeep, Arslan, Shukaib, Al Malki, Monzr M., Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Artz, Andrew, Stewart, Forest Marc, Smith, Eileen Patricia, Stein, Anthony, Marcucci, Guido, Nakamura, Ryotaro, Pullarkat, Vinod, Aldoss, Ibrahim, Mei, Matthew Genyeh

“…Background Use of tyrosine kinase inhibitor (TKI) maintenance following allogeneic hematopoietic cell transplantation (HCT) in Philadelphia chromosome positive…”
Get full text